BridgeBio (BBIO) director McCormick awarded RSUs, options and updates holdings
Rhea-AI Filing Summary
BridgeBio Pharma director Frank McCormick reported new equity awards and updated his holdings. He received 3,990 restricted stock units, each representing one share of common stock, and a stock option covering 5,277 shares at an exercise price of $68.92 per share.
The RSUs and the option shares both vest in full on June 22, 2027, conditioned on his continued service on the board. After these awards, he holds 10,579 shares directly and 756,665 shares indirectly through the Francis P. McCormick Rev Trust.
The filing also corrects a previously reported transfer of 352,290 shares that did not occur and clarifies that 428,976 shares were transferred from his direct holdings to his trust account on June 3, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 3,990 shares
Net Buy
3 txns
Insider
MCCORMICK FRANK
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 5,277 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 3,990 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 5,277 shares (Direct);
Common Stock — 10,579 shares (Direct);
Common Stock — 756,665 shares (Indirect, By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017)
Footnotes (6)
- F1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
- F2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- F3. The Reporting Person previously reported a transfer of 352,290 shares on a Form 4 filed June 25, 2024. The reported transfer did not occur, and no change in beneficial ownership took place at that time. The ownership amounts reported herein reflect the Reporting Person's correct holdings and the transfer described in Footnotes 4 and 5.
- F4. Excludes 428,976 shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on June 3, 2026.
- F5. Includes 428,976 shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on June 3, 2026.
- F6. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
Key Figures
RSU grant: 3,990 units
Option grant size: 5,277 shares
Option exercise price: $68.92/share
+5 more
8 metrics
RSU grant
3,990 units
Restricted stock units granted June 22, 2026
Option grant size
5,277 shares
Stock option covering common stock
Option exercise price
$68.92/share
Exercise price of stock option
Equity vesting date
June 22, 2027
Vesting date for RSUs and option shares
Direct holdings after award
10,579 shares
Common stock held directly after transactions
Indirect holdings via trust
756,665 shares
Common stock held indirectly through trust
Shares moved to trust
428,976 shares
Transferred from direct holdings to trust on June 3, 2026
Previously misreported transfer
352,290 shares
Transfer reported in 2024 that did not occur
Key Terms
restricted stock units ("RSUs"), beneficial ownership, trust account, stock option, +1 more
5 terms
restricted stock units ("RSUs") financial
"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
beneficial ownership financial
"no change in beneficial ownership took place at that time."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
trust account financial
"were transferred to the Reporting Person's trust account on June 3, 2026."
A trust account is a special bank or brokerage account where assets are held and managed by a designated person or firm (the trustee) for the benefit of another person or group (the beneficiary). It matters to investors because it separates assets from personal or corporate funds, can protect assets, control how and when money is used, and may affect tax or legal rights—think of it as a locked drawer opened only under agreed rules.
stock option financial
"The shares underlying the stock option vest in full on June 22, 2027"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price": "68.9200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
What equity awards did BridgeBio (BBIO) director Frank McCormick receive?
Frank McCormick received 3,990 restricted stock units and a stock option for 5,277 shares at an exercise price of $68.92. These awards were granted as part of his compensation for serving on BridgeBio’s board of directors.
When do Frank McCormick’s new BridgeBio (BBIO) RSUs and options vest?
Both the 3,990 restricted stock units and the stock option for 5,277 shares vest in full on June 22, 2027. Vesting is subject to McCormick’s continued service on BridgeBio Pharma’s board of directors through that date.
What correction did BridgeBio (BBIO) disclose about Frank McCormick’s prior Form 4?
The filing states a previously reported transfer of 352,290 shares on a June 25, 2024 Form 4 did not occur. As a result, no change in McCormick’s beneficial ownership happened then, and current amounts reflect his correct holdings.
What is the exercise price and term of Frank McCormick’s new BridgeBio (BBIO) stock option?
The new stock option covers 5,277 BridgeBio common shares at an exercise price of $68.92 per share and expires on June 21, 2036. The shares underlying the option vest in full on June 22, 2027, subject to continued board service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
